{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/psoriasis/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"409aaeee-7f7b-53cc-afdc-9ea9034984d6","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field aec5f194-64df-4a20-8a45-2ac460a47679 --><h2>Changes</h2><!-- end field aec5f194-64df-4a20-8a45-2ac460a47679 -->","summary":null,"htmlStringContent":"<!-- begin item 8dc287d9-0850-4481-838a-9fcf8ee109ed --><!-- begin field 232c2016-09c1-49c9-b5c1-c66dc6fe4fde --><p><strong>December 2020 </strong>— minor update. A typographical error has been corrected.</p><p><strong>April 2020</strong> — minor update. New management scenario created to provide information regarding COVID-19. </p><p><strong>March 2018</strong> — minor update. New product availability, Ilumya™ has been approved for the treatment of moderate-to-severe plaque psoriasis. </p><p><strong>October to November 2017</strong> — reviewed. A literature search was conducted in October 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. The topic has undergone minor restructuring. The recommendations on the diagnosis and management of psoriasis have been amended in line with current evidence. An additional node has been added to the <em>Management</em> section on <em>Specialist investigations and treatment</em>. The section on <em>Topical corticosteroids</em> has been removed from the <em>Prescribing information</em> section, and replaced with links to the CKS topic on <em>Corticosteroids - topical (skin), nose, and eyes</em>.</p><!-- end field 232c2016-09c1-49c9-b5c1-c66dc6fe4fde --><!-- end item 8dc287d9-0850-4481-838a-9fcf8ee109ed -->","topic":{"id":"a3ecec3a-acde-5ece-90b0-dedc6c08db8b","topicId":"c8702cb0-6f30-44e4-832b-ab9161ee384a","topicName":"Psoriasis","slug":"psoriasis","lastRevised":"Last revised in December 2020","chapters":[{"id":"d0c39045-d8df-5a7e-bd7d-96fef3aefc3a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6e22adaa-de33-5d1c-bc1f-9740d238c5a2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a7c9da10-9760-5143-bf20-167f1e832103","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"409aaeee-7f7b-53cc-afdc-9ea9034984d6","slug":"changes","fullItemName":"Changes"},{"id":"1677a6dc-645a-58fe-8ed8-8bdfcface768","slug":"update","fullItemName":"Update"}]},{"id":"ca38cddf-4680-5dc4-a0df-79ab9910a789","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fc350387-9e56-5f4b-b454-3cfa5ecd9a2a","slug":"goals","fullItemName":"Goals"},{"id":"00a9f2b3-e7b5-5394-9762-48d34a0dc722","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"400cbb71-cb76-5ee3-824a-738bc6249b3b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ad046045-038c-5b75-8f42-50343d5b824e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"773d3740-99b6-5a32-b555-968b2efb0b8b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0692cf2f-4b3d-5098-afe3-ac07b3c763ff","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d16fcd88-1021-5238-86e4-2452eee7fdde","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ef476810-392e-5b83-b527-fe921221cc0b","slug":"definition","fullItemName":"Definition"},{"id":"fb1e0af3-fd46-562a-83d6-33a31640b639","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d6b8dab4-762f-5e9e-a83e-35a3652483b3","slug":"trigger-factors","fullItemName":"Trigger factors"},{"id":"70837c8d-73ae-5bc4-a042-949d31503ca3","slug":"associated-conditions","fullItemName":"Associated conditions"},{"id":"e90f3736-0e28-53fa-8295-309df8aa8e00","slug":"complications","fullItemName":"Complications"},{"id":"9523ad16-6e73-50ba-94bd-64c548f5c313","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4d0deda5-f89f-59e7-8978-1c3337afdcfe","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"067d150c-d6d4-5992-9319-f86bfeecca88","slug":"assessment","fullItemName":"Assessment"},{"id":"58b4da96-dda6-596b-9570-fd5070898cfe","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"27af05e5-54bf-5bc5-ba76-d1b8f18e7252","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"eaab9e94-c74e-5c84-ba14-d8db3a6dd1e8","fullItemName":"Management","slug":"management","subChapters":[{"id":"82ee7501-0589-54c2-8df7-5a9256a3f1d0","slug":"pustular-or-erythrodermic-psoriasis","fullItemName":"Scenario: Pustular or erythrodermic psoriasis"},{"id":"e4183760-c129-567e-9211-cef27ef68100","slug":"trunk-limbs","fullItemName":"Scenario: Trunk and limbs"},{"id":"6a7e9d56-0d17-5c90-b835-822367fbcd3e","slug":"scalp-psoriasis","fullItemName":"Scenario: Scalp psoriasis"},{"id":"9c7cebad-a77f-5fa8-811a-50815577a51c","slug":"facial-flexural/genital-psoriasis","fullItemName":"Scenario: Facial/flexural/genital psoriasis"},{"id":"6fbadcef-730e-5874-97ad-53e1f12bd5e3","slug":"guttate-psoriasis","fullItemName":"Scenario: Guttate psoriasis"},{"id":"a069495e-d2fe-5fca-9799-1b5f4f874033","slug":"nail-psoriasis","fullItemName":"Scenario: Nail psoriasis"},{"id":"08dc9427-b5ec-59f4-b47b-72a666beacef","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ce3be64b-a968-59e2-b206-5a055de98330","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"520d3bb6-49cf-5f46-b761-9df1c712ad28","slug":"emollients","fullItemName":"Emollients"},{"id":"2a68bcd1-b92f-579a-955e-f4638d00073f","slug":"vitamin-d-preparations","fullItemName":"Vitamin D preparations"},{"id":"39f1a594-6e44-59b9-bb85-a277475d7386","slug":"salicylic-acid","fullItemName":"Salicylic acid"},{"id":"325d4c77-192a-5152-971f-a5f4f1d64fc7","slug":"coal-tar-products","fullItemName":"Coal tar products"},{"id":"302b90f5-e0d6-53cc-88ce-6a06def02b51","slug":"dithranol-short-contact","fullItemName":"Dithranol (short-contact)"}]},{"id":"00678b76-cc05-5d69-a6be-8760727fb9cf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"91ae130b-06c7-538c-a295-af4bf7a3dbf1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"358d84df-224b-5d6b-96cd-c52dfe00a200","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"383c93f2-ae1f-5c75-af43-3a9a448c1669","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3703e9fb-0103-5fe6-a0ed-192226578ed6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d248a57f-2b73-5c2f-89c5-18ed618c3535","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e35fcef8-37a3-5afe-9250-f527d2c6e017","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7314bc52-4cb9-530c-a905-917edad0de05","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a7c9da10-9760-5143-bf20-167f1e832103","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"bb7bde44-5578-50ea-b60c-e0404eca3993","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 58212da9-449a-49cc-a3ce-79dcf65e6192 --><h3>Previous changes</h3><!-- end field 58212da9-449a-49cc-a3ce-79dcf65e6192 -->","summary":null,"htmlStringContent":"<!-- begin item ca7d44f7-dcf8-433b-b40e-caa6e9d7bb28 --><!-- begin field 09e29b95-7798-48a2-b069-f0793237c3d1 --><p><strong>July 2017</strong> — minor update. Text added to the section on contraindications for topical vitamin D preparations, to reflect changes to the manufacturer's Summary of Product Characteristics.</p><p><strong>December 2016</strong> — minor update. The product availability section has been updated, as a foam preparation containing calcipotriol and betamethasone is now available. Information that any of the systemic adverse effects associated with oral corticosteroids could also occur with topical corticosteroids has been added to this topic.</p><p><strong>September 2014 </strong>— minor update to the prescribing information to reflect the discontinuation of Carbo-Dome<sup>®</sup> topical cream preparation.</p><p><strong>May 2013 </strong>— minor update to the text to reflect advice issued by the Medicines and Healthcare products Regulatory Agency (MHRA) regarding aqueous cream.</p><p><strong>December 2012 </strong>— reviewed. A literature search was conducted in November 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. There are several changes to the recommendations, following the publication of guidance from the National Institute for Health and Clinical Excellence <em>Assessment and management of psoriasis</em>.</p><p><strong>March 2011 </strong>— update to the text to reflect recommendations from a guideline published by the Scottish Intercollegiate Guidelines Network (SIGN) <em>Diagnosis and management of psoriasis and psoriatic arthritis in adults</em>. Issued in June 2011.</p><p><strong>August 2010 </strong>— minor update. The usage instructions for calcipotriol combined with betamethasone products have been clarified. Issued in September 2010.</p><p><strong>February to May 2010 </strong>— this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 09e29b95-7798-48a2-b069-f0793237c3d1 --><!-- end item ca7d44f7-dcf8-433b-b40e-caa6e9d7bb28 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}